Skip to main content

Drug Interactions between streptokinase and Uribel Tabs

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

streptokinase phenyl salicylate

Applies to: streptokinase and Uribel Tabs (benzoic acid / hyoscyamine / methenamine / methylene blue / phenyl salicylate)

MONITOR CLOSELY: Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.

MANAGEMENT: Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment. Local guidelines and prescribing information for individual thrombolytic drugs should be consulted for further recommendations.

References (8)
  1. (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc
  2. (2001) "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical
  3. (2001) "Product Information. Activase (alteplase)." Genentech
  4. (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
  5. (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
  6. (2001) "Product Information. TNKase (tenecteplase)." Genentech
  7. Harder S, Klinkhardt U (2000) "Thrombolytics: drug interactions of clinical significance." Drug Saf, 23, p. 391-9
  8. Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S

Drug and food interactions

Moderate

hyoscyamine food

Applies to: Uribel Tabs (benzoic acid / hyoscyamine / methenamine / methylene blue / phenyl salicylate)

GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.

MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.

References (1)
  1. Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer